Accordingly, CRM1 inhibitors could be of interest to test as novel remedies for inhibition of malignant T cells in CTCL as it regulates the activity of JAK3/STAT3/SOCS3, a key signaling pathway in malignant transformation in CTCL [17]. Here, XPO1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.